Analysed TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) News Sources
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses
03-04-2026
yahoo.com
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors
03-04-2026
yahoo.com
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31-03-2026
yahoo.com
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
23-03-2026
yahoo.com
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
22-03-2026
fool.com
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance
09-03-2026
yahoo.com
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating
06-03-2026
yahoo.com
What is the current price of TARSUS PHARMACEUTICALS INC (TARS:NASDAQ)?
The current price of TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) is $72.56.
TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) absolute price change since previous trading day?
The absolute price change of TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) since the previous trading day is $0.135.
TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) percentage price change since previous trading day?
The percentage price change of TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) since the previous trading day is 0.1864%.
What is the most recent average sentiment score for TARSUS PHARMACEUTICALS INC (TARS:NASDAQ)?
The most recent average sentiment score for TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for TARSUS PHARMACEUTICALS INC (TARS:NASDAQ)?
The most recent sentiment for TARSUS PHARMACEUTICALS INC (TARS:NASDAQ) is .
SEC-8K** Filing Available For TARSUS PHARMACEUTICALS INC (TARS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.